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ABSTRACT - Purpose. To evaluate the influence of co-administered vehicles on in vitro dissolution in 
simulated gastric fluid of crushed immediate release tablets as an indicator for potential drug bioavailability 
compromise. Methods. Release and dissolution of crushed amlodipine, atenolol, carbamazepine and 
warfarin tablets were tested with six foods and drinks that are frequently used in the clinical setting as 
mixers for crushed medications (water, orange juice, honey, yoghurt, strawberry jam and water thickened 
with Easythick powder) in comparison to whole tablets. Five commercial thickening agents (Easythick 
Advanced, Janbak F, Karicare, Nutilis, Viscaid) at three thickness levels were tested for their effect on the 
dissolution of crushed atenolol tablets. Results. Atenolol dissolution was unaffected by mixing crushed 
tablets with thin fluids or food mixers in comparison to whole tablets or crushed tablets in water, but 
amlodipine was delayed by mixing with jam. Mixing crushed warfarin and carbamazepine tablets with 
honey, jam or yoghurt caused them to resemble the slow dissolution of whole tablets rather than the faster 
dissolution of crushed tablets in water or orange juice. Crushing and mixing any of the four medications 
with thickened water caused a significant delay in dissolution. When tested with atenolol, all types of 
thickening agents at the greatest thickness significantly restricted dissolution, and products that are primarily 
based on xanthan gum also delayed dissolution at the intermediate thickness level. Conclusions. Dissolution 
testing, while simplistic, is a widely used and accepted method for comparing drug release from different 
formulations as an indicator for in vivo bioavailability. Thickened fluids have the potential to retard drug 
dissolution when used at the thickest levels. These findings highlight potential clinical implications of the 
addition of these agents to medications for the purpose of dose delivery and indicate that further 
investigation of thickened fluids and their potential to influence therapeutic outcomes is warranted. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION  
 
The oral route is the most convenient for 
medication administration. Solid dose forms such 
as tablets, pills or capsules are preferred for the 
oral delivery of active pharmaceutical ingredients, 
providing accuracy in the dose, maximal storage 
stability, low cost, as well as patient adherence 
and compliance with the dosage regime. 
However, medications often cannot be safely 
administered to a patient if the oral route is 
compromised. 
Anatomical and physiological complications 
associated with the oral, pharyngeal and 
esophageal phases of swallowing are known as 
dysphagia (1). A consequence of dysphagia can 
be aspiration of food, drink or medication leading 
to risk of airway obstruction or pneumonia. 
Dysphagia is generally associated with other 
disease-related conditions such as Parkinson’s 
disease, multiple sclerosis, stroke, cancer and 
dementia and consequently is most prevalent in 
the older population (2). Individuals who do not 
have a problem with swallowing food and drink 
can still manifest a psychological aversion to 
swallowing solid dosage forms (3). Factors such 
as the type of formulation, size, shape and surface 
characteristics of medications as well as a 
patient’s body position are crucial for the delivery 
of medications (3, 4). 
There have been some attempts to quantify 
the extent to which difficulties swallowing solid 
medications affect the population. 
________________________________________ 
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In a study of 792 customers (69-89 yrs) of 
community pharmacies in England who 
pharmacists suspected may have difficulties 
swallowing tablets, 60% acknowledged having 
problems (5). Difficulties swallowing tablets and 
capsules accounted for an average of 22% of 
nursing home residents in the UK, based on a 
survey of 540 nurses (6). In the USA, up to 40% 
of 64 residents in an aged care facility reported 
having difficulties swallowing tablets and 
capsules while 20% of a control group with an 
average age of 30 had the same problem (7). 
Difficulty swallowing solid dose medication 
is ideally addressed by the prescriber finding an 
alternative dosage form, which may require the 
prescribed medicine to be compounded into a 
liquid preparation or a change to a different 
medicine (8). However, in the absence of an 
alternative, solid dosage forms are invariably 
modified by patients and carers into a form that 
can be swallowed. For example, in the UK, 61% 
of staff in nursing homes crushed or opened 
medications for patients (6), and 25% of oral 
doses were altered in a mental institution (9). In 
Australia, medications were altered before being 
given to the patient in 34% of 408 observations, 
in aged care facilities (10) and nurses at 79% of 
97 health facilities altered medicines to ease 
administration (11). This commonly involves 
crushing tablets or opening capsules and mixing 
the contents into food or fluids such as apple 
sauce, jam, custard, yoghurt, honey or juice (11-
17). Patients suffering from dysphagia often have 
their fluid and dietary intake managed by the use 
of thickening agents in order to ensure safe 
swallowing and avoid aspiration into the airway 
(18). Medications for these patients may also be 
delivered by crushing and mixing with ‘thickened 
fluids’(11), which are liquids such as water or 
juice thickened to the required viscosity. There 
are generally three thickness levels used, with the 
viscosity prescribed often increasing with severity 
of dysphagia (18). 
While it is generally recognised by health 
professionals that tablets or capsules that are 
designed to have modified release properties 
should not be crushed due to the potential for 
toxicity, other medications are not often 
associated with any potential for negative 
outcome (19). Immediate release solid 
medications are designed to disintegrate and 
dissolve quickly in the gastrointestinal tract, so 
crushing may be expected to result simply in a 
slightly faster absorption. However, while this is 
the case for some medications (20, 21) crushing 
could result in higher bioavailability (22, 23) due 
to enhanced dissolution and mass transfer, but it 
may also lead to sub-therapeutic drug levels due 
to loss of the dose during crushing and transfer 
(10, 24). Additionally, it is recognised that 
delivering medications with food or drink may 
impact drug bioavailability, with fruit juices such 
as grapefruit, orange or apple juice affecting 
absorption of numerous medicines (25-27) and 
foods potentially affecting physiologic conditions 
such as gastric emptying (17, 28). Generally, 
crushing tablets or opening capsules and mixing 
with a small quantity (e.g. two tablespoons) of 
food such as pudding, yoghurt or apple sauce does 
not significantly alter bioavailability (12-15). 
However, mixing crushed phenytoin tablets with 
pudding resulted in impaired absorption in 
comparison to the use of apple sauce (16) and 
mixing enteric-coated beads of didanosine with 
yoghurt or apple sauce delayed absorption (17). 
The effect of mixing crushed tablets into 
thickened fluids on drug absorption has not 
previously been addressed, but there is evidence 
that absorption of whole digoxin, penicillin and 
metformin tablets may be reduced when 
consumed with guar gum as a source of dietary 
fibre (29, 30) and dissolution rate of benzoic acid 
tablets is reduced when tested in dissolution 
media thickened using xanthan gum or guar gum 
(31). Alterations in bioavailability such as this are 
of particular concern for drugs that have a narrow 
therapeutic index because the concentration 
absorbed into the blood stream may not reach that 
required to elicit the therapeutic effect. 
This study aimed to evaluate the influence of 
thickened fluids and other commonly used food 
and liquid vehicles (jam, yoghurt, juice and 
honey) on drug dissolution from crushed tablets. 
The in vitro dissolution test performed under 
specific conditions can be used as a prognostic 
tool for evaluating the bioavailability of certain 
drugs (32). While it cannot entirely replace in vivo 
testing, in vitro dissolution testing can provide 
insights on the physicochemical process involved 
and provide an indication of whether in vivo tests 
are warranted (33).  
 
METHODS 
 
Materials 
Four generic immediate release formulations (IR) 
were used. Amlodipine besylate 10 mg tablets 
(Sandoz) and atenolol 50 mg tablets (Sandoz) 
represent some of the most common medicines 
modified in hospitals (11). Carbamazepine 200 
mg tablets (Sandoz) and warfarin 5 mg tablets 
(Marevan) represent medications with a narrow 
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therapeutic index. These drugs were also chosen 
to provide a range of solubilities in water and for 
the presence of a chromophore within the 
chemical structure to enable analysis using UV 
spectroscopy. There were three liquids used for 
drug delivery in this study (water, orange juice 
and honey), two semi-solid food vehicles (jam, 
yoghurt), and six commercial food thickening 
agents (Easythick, Easythick Advanced, Janbak F, 
Karicare, Nutilis, Viscaid) (Tables 1 and 2). 
Thickened fluids were prepared as directed by the 
manufacturer at three thickness levels indicated 
for dysphagic patients (18); mildly thick (level 
150), moderately thick (level 400) and extremely 
thick (level 900). Spoon measurements of the 
powder were converted to weight (Table 2) and 
added into water to reach the desired percentage 
(% w/v). Mixtures were stirred using a stick 
blender for 3 minutes until the powder was 
dispersed. Samples were maintained at 4°C 
overnight to ensure consistency and 
microbiological stability, and then equilibrated at 
room temperature before testing. 
 
Vehicle characterisation 
Vehicles were agitated by spoon for 5 seconds. 
pH was measured using a S220 SevenCompact 
pH meter (Mettler-Toledo, Port Melbourne, Vic) 
and a pre-calibrated pycnometer was used for 
density measurements. Rheology of food fluids 
and thickening agents was measured using two 
rheometers, chosen as appropriate to the vehicle: 
AR 1500ex (TA Instruments) with a large vane or 
concentric cylinder at 37°C, or HAAKE MARS 
III (Thermo Fisher Scientific, Scoresby, Vic) with 
cone and plate fixture, 35 mm diameter, 2° angle 
at 37°C. The effect of the thickened fluids on 
dissolution media viscosity was measured using 
an AR-G2 (TA Instruments) with cone and plate 
fixture, 40 mm diameter, 2° angle at 37°C  for a 
sample of media taken at 15 minutes and 3 hours 
into a dissolution test of each thickener at level 
900. The viscosity of dissolution media 
containing thickener at level 900 that was 
completely dispersed within the media was 
measured using an AR 1500ex with concentric 
cylinder at 37°C; complete dispersion was 
achieved by adding the quantity of thickener 
powder that would be used to prepare 15 g 
thickened fluid at level 900 into 900 ml 
dissolution media. The majority of test vehicles 
were non-Newtonian with a viscosity that is 
highly dependent on shear rate. However, while 
the rheological curves for each sample was 
measured, for brevity and simplicity, the value for 
viscosity reported herein is η50, i.e. the 
measurement at 50 s-1. 
 
 
Table 1.  Physicochemical characteristics and rheological attributes of the food and drink vehicles used in this study. 
Vehicle Brand Type Compositiona pH Density Viscosity (cP)b Type of flow 
Water - purified  water 6.7 1.00 0.8 Newtonianc  
Orange 
juice 
Just Juice pulp free orange juice, water, 
sugars, preservatives 
3.2 1.04 2.76 Newtonianc
Honey Capillano Australian honey 3.8 1.42 3750 Newtonianc
Jam Golden 
Circle 
strawberry strawberries, pectin, 
food acids, natural 
colour, sugar 
3.0 1.32 3120 Non- Newtonianc 
Yoghurt Yoplait 
 
vanilla 
flavour 
milk, solid, sugar, 
cream, fructose, 
thickeners (corn 
starch, halal gelatine), 
preservatives, acidity 
regulator, vanilla bean 
seed, natural colours, 
live yoghurt cultures: 
Streptococcus 
thermophilus, 
Acidophilus, 
Bifidobacterium 
4.5 1.08 723 Non- Newtonianc 
a taken from the product label; b measured at 50 s-1and 37°C; c AR 1500ex  
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Drug release and dissolution 
One (amlodipine, carbamazepine) or two 
(atenolol, warfarin) tablets were crushed using a 
mortar and pestle; tablet quantities were chosen to 
produce adequate drug concentrations for 
spectrophotometric detection. The powder 
obtained was then transferred into a 30 mL plastic 
cup filled with 15 g of the vehicles, as an 
estimation of the quantity typically used for 
medication delivery. Powder medications were 
incorporated by hand with a metallic spatula and 
agitated for one minute to disperse the solid. For 
comparison, whole tablets delivered with 15 mL 
water were tested. USP dissolution test apparatus 
II (VK7000, Varian, Mulgrave, Vic) was used 
with 900 mL of pH 1.2 simulated gastric fluid 
(SGF) without enzymes (34) at 37°C and a paddle 
rotation speed of 50 rpm (34, 35). Dissolution 
media recommended for each drug varied 
between the USP and BP; in this study a single 
standard environment was chosen to allow direct 
comparison of multiple drugs and multiple 
vehicles. Dispersions of the drug and the vehicle 
were placed into the dissolution vessel and 5 mL 
samples were collected at 1, 3, 5, 10, 15, 20, 30, 
45, 90, 150 and 180 minutes through a stainless 
steel cannula assembled with full flow filter (10 
μm, Varian) into 5 mL plastic syringes. 5 mL of 
fresh SGF was replaced immediately into 
dissolution vessels at every sampling point. 
Dissolution tests were also performed for the 
vehicles without drugs as the control. Samples 
were filtered through 0.45 μm nylon membranes 
(Millipore). Samples containing yoghurt were 
additionally centrifuged for 10 min at 4000 rpm 
prior to filtration. Calibration curves of each drug 
in SGF were prepared using stock solutions 
containing one (amlodipine, carbamazepine) or 
two (atenolol, warfarin) tablets dissolved in 1 L 
SGF and absorbance measured at 240 nm 
(amlodipine), 274 nm (atenolol), 280 nm 
(warfarin) and 285 nm (carbamazepine) using a 
Spectrophotometer Hitachi U-1900, (Scientific 
Instrument & Optical Sales, Brisbane, Qld). To 
account for background absorbance associated 
with the vehicles, results for the controls were 
subtracted from the absorbance of the vehicle 
containing drug. Cumulative percentage of the 
drug being dissolved was obtained and plotted 
against sample time. All tests and calibration 
curves were repeated in triplicate. 
In the first experiment, crushed tablets of all 
four medications (amlodipine, atenolol, 
carbamazepine, warfarin) were tested for their 
release from three liquids (water, orange juice, 
honey), two semi-solid food vehicles (jam, 
yoghurt) and one thickened fluid (Easythick, level 
900). Whole tablets with water were also tested 
for comparison. Additionally, crushed warfarin 
mixed with Easythick (level 900) was compared 
with crushed warfarin mixed with water using a 
medium of SGF containing 3.2 g/L pepsin (800-
2500 units/mg pepsin from porcine gastric 
mucosa, Sigma-Aldrich) to check whether this 
version of the dissolution media prescribed by the 
BP could improve drug release from the thickened 
fluid (34). In the second experiment, dissolution 
from five other thickening agents (Easythick 
Advanced, Janbak F, Karicare, Nutilis, Viscaid) 
were investigated at three thickness levels (150, 
400, 900) using crushed atenolol tablets. Whole 
and crushed atenolol tablets in water were re-
tested at the same time for comparison. 
The results were analysed for differences in 
drug dissolution from food vehicles and 
thickening agents with one way ANOVA 
(p<0.005) and a Bonferroni post hoc test using 
GraphPad Prism version 5 (GraphPad software, 
San Diego, CA, USA). 
 
RESULTS  
 
Amlodipine and atenolol whole tablets exhibited 
very rapid dissolution in SGF, with more than 
85% of the drug dissolved in the first 10 minutes 
and complete dissolution achieved by 30 minutes 
(Figure 1 a,c). Dissolution of carbamazepine and 
warfarin tablets was slower, taking 2 and 2.5 
hours respectively to reach 85% (Figure 1 e,g). As 
a general guide, the amount of drug measured in a 
dissolution test for immediate release tablets 
should be not less than 85% of the labeled amount 
within 30 minutes according to the FDA (36). 
Whole tablets of amlodipine and atenolol met 
these criteria but carbamazepine and warfarin did 
not (Table 3). However, it should be noted that 
the dissolution of carbamazepine tablets should be 
in a media that includes a surfactant and at 75 rpm 
according to the USP, and dissolution of warfarin 
should be assessed in water at 50 rpm (USP) or at 
pH 6.8 and 100 rpm (BP); these environments 
would be expected to be more conducive to 
dissolution of these particular drugs. Crushing the 
tablets and delivering with water resulted in faster 
dissolution, with carbamazepine and warfarin 
tablets reaching 85% dissolution within 60 and 20 
minutes respectively (Figure 1 e,g). 
Mixing the crushed tablets with orange juice, 
as an alternative Newtonian thin fluid that was 
similar in viscosity to water (Table 1), resulted in 
similar dissolution profiles to crushed tablets in 
water for all of the medications (Figure 1 b,d,f,h). 
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Honey, also a Newtonian fluid but considerably 
higher in viscosity (Table 1), caused only a small 
delay in dissolution for amlodipine and atenolol 
and this had no influence on % dissolved at 30 
minutes (Table 2). Carbamazepine dissolution 
appeared to be slower in honey than water (Figure 
1 f), with only 40% dissolved at 30 minutes 
instead of 77%, but this was not statistically 
significant (Table 3). However, honey 
significantly slowed dissolution of warfarin when 
compared with crushed tablets in water (Figure 1 
h), reducing the proportion dissolved at 30 
minutes to 44% instead of 90% (Table 3). In fact 
the dissolution profiles for carbamazepine and 
warfarin in honey more closely resembled the 
dissolution of the whole tablets than crushed 
tablets in water. 
The use of jam or yoghurt as a vehicle, both 
thick fluids with non-Newtonian properties (Table 
1), produced variable results. For atenolol, 
yoghurt was no different to orange juice or water, 
but it slowed dissolution in a similar way to honey 
for amlodipine and warfarin (Figure 1; Table 3). 
Jam generally reduced dissolution rate to a greater 
extent than yoghurt (Figure 1); the slight delay in 
dissolution for atenolol had no influence on the 
measurement at 30 minutes, but the slowed 
dissolution for amlodipine and warfarin had an 
impact (Table 3). The effect of yoghurt and jam 
on carbamazepine dissolution was large, reducing 
the 30 minute measurement to 51% and 37% 
respectively, which were more similar to 
dissolution of the whole tablet (57%) than crushed 
tablet in water (77%) but, due to variation 
between replicates within the carbamazepine 
experiment (particularly with yoghurt), these 
changes were not statistically significant (Table 
3). 
 
 
 
Table 2.  Physicochemical characteristics and rheological attributes of the commercial thickeners used in this study. 
Spoon measurements indicated for each product were converted to weight and added to water to give the concentration 
(% w/v) for each thickness level. 
Vehicle Brand 
 
Compositiona Thickness Conc. 
(%w/v) 
pH Density Viscosity 
(cP)b 
Type of flow 
Easythick Flavour 
Creations 
maltodextrin, 
xanthan gum 
Level 900 7.3 5.6 1.01 767 Non- Newtoniand 
Easythick 
Advanced 
Flavour 
Creations 
maltodextrin, 
xanthan gum 
vitamin C, 
calcium 
chloride 
Level 900 4.32 4.4 1.01 1250 Non- Newtonianc 
Level 400 1.70 4.8 1.00 414 
Level 150 0.87 4.8 1.00 176 
Janbak F Janbak 
Industries  
xanthan gum  Level 900 2.2 6.0 0.99 1252 Non- Newtonianc 
  Level 400 1.15 6.2 1.00 465 
  Level 150 0.76 6.2 1.00 260 
Karicare  Nutricia maltodextrin, 
maize starch, 
carob bean 
gum 
Level 900 40 5.1 1.03 1711 Non- Newtonianc 
  Level 400 20 5.3 1.03 483 
  Level 150 8 5.4 1.00 15 
Nutilis  
 
 
 
Nutricia maltodextrin, 
modified 
maize starch, 
tara gum, 
xanthan gum, 
guar gum 
Level 900 16 5.6 1.02 4090 Non-Newtonianc  
Level 400 12 5.7 1.02 3380 
Level 150 8 5.7 1.02 1860 
Viscaid Janbak 
Industries 
guar gum Level 900 1.4 6.3 0.99 1681 Non-Newtonianc  
Level 400 0.67 6.2 0.99 465 
Level 150 0.33 6.5 0.99 47 
a taken from the product label; bmeasured at 50 s-1 and 37 °C; c AR 1500ex; d HAAKE MARS III 
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Easythick at level 900 caused the greatest 
restriction in drug release for all four medications 
tested. Atenolol, which was largely unaffected by 
any of the other vehicles, exhibited only 50% 
release by 30 minutes (Table 3) and took 3 h to 
reach 85% (Figure 1 d). Amlodipine also released 
only 50% by 30 minutes, a significant reduction 
(Table 3), but carbamazepine and warfarin 
reached only 14% by 30 min and 40 - 50% after 3 
h (Figure 1). There was no additional release of 
warfarin from thickened fluid when tested using 
SGF containing pepsin as the dissolution medium 
(Figure 2), which is an alternative simulation of 
the gastric environment (34, 35). 
The delayed release of four crushed 
medications by Easythick at level 900 led to the 
subsequent investigation of drug release from a 
further five commonly used thickening agents, 
with consideration of the preparation thickness 
(Figure 3). Using atenolol tablets as the model 
drug, at thickness level 150 there was a minor and 
non-significant delay in dissolution; at least 85% 
of the medication was released and dissolved 
within 30 minutes with all of the products except 
Janbak F which allowed dissolution of only 76% 
(Table 4). It was observed that when added to the 
dissolution vessel, thickened fluids containing the 
crushed tablets initially became dispersed and 
mixed with SGF but later formed a single lump, 
and that lump only broke into smaller pieces for 
Nutilis. 
At level 400, Easythick Advanced and Janbak 
F significantly slowed the dissolution of atenolol 
(Figure 3), allowing only 46 and 68% dissolution 
respectively at 30 minutes in comparison to 87 – 
98% for the other thickened fluids at the same 
thickness and the whole tablet or crushed tablet 
with water (Table 4). Observations of the samples 
loaded into the vessel indicated that either they 
remained as a single mass for the whole 
experiment (Easythick Advanced, Janbak F and 
Karicare) or broke into small pieces (Nutilis, 
Viscaid) and later formed a single clump 
(Nutilis). 
When used at level 900, all of the thickened 
fluids retarded dissolution when compared with 
whole tablets or crushed tablets in water, with 36 
– 62% release in 30 minutes (Table 4) and a great 
deal of variation between replicate tests (Figure 
3). The samples were all observed to remain in a 
single lump for the whole experiment, avoiding 
complete mixing with the dissolution media. Lack 
of mixing was confirmed for level 900 thickeners 
by testing dissolution media viscosity at 15 
minutes and 3 hours into the dissolution test, with 
all values being lower than measured when the 
thickener was completely dispersed in the 
dissolution media (Table 5). 
 
DISCUSSION  
 
The most notable outcome from this study was 
that thickened fluids, prepared using commercial 
powder thickeners that are designed to produce a 
thickness that improves the likelihood of 
dysphagic patients to be able to safely swallow 
liquids, can significantly delay dissolution of 
drugs mixed into them.  
 
 
 
Table 3.  The percentage dissolution (mean ± standard error; n = 3) in simulated gastric fluid at 30 minutes for 
amlodipine, atenolol, carbamazepine and warfarin whole tablets delivered with 15 g water and crushed tablets mixed 
into 15 g of various vehicles. Within each column, measurements with the same superscript letter are not significantly 
different (P<0.05). 
 Percentage of drug dissolved at 30 minutes 
 Amlodipine Atenolol Carbamazepine Warfarin 
Whole tablets 100.7 ± 1.5 a 98.1 ± 1.1 a 57.0 ± 2.8 ac 44.9 ± 7.1 a 
Crushed tablets:     
 Water 99.5 ± 0.4 a 99.8 ± 0.2 a 76.7 ± 1.0 a 89.5 ± 1.3 b 
 Orange juice 100.2 ± 0.3 a 100.0 ± 0.0 a 78.7 ± 2.4 a 79.3 ± 7.4 b 
 Honey 94.3 ± 2.8 ac 99.2 ± 0.5 a 40.1 ± 2.9 ac 43.6 ± 3.2 a 
 Strawberry jam 67.7 ± 4.4 bc 100.0 ± 0.0 a 37.4 ± 2.4 ac 37.8 ± 5.1 ad 
 Yoghurt 82.8 ± 13.5 acd 100.5 ± 3.0 a 51.2 ± 11.4 ac 53.0 ± 1.3 a 
 Easythick (level 900) 52.4 ± 5.6 bd 50.1 ± 2.7 b 13.4 ± 4.0 bc 14.9 ± 1.0 cd 
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Figure 1.  Dissolution of amlodipine (a,b), atenolol (c,d), carbamazepine (e,f) and warfarin (g,h) in simulated gastric 
fluid using whole tablets and crushed tablets mixed with water (a,c,e,g) and crushed tablets mixed with orange juice, 
honey, jam, yoghurt and thickened fluid (Easythick at thickness level 900) (b,d,f,h). The data shows mean ± standard 
error for 3 replicates. 
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Figure 2.  Dissolution in simulated gastric fluid with 
and without pepsin for crushed warfarin tablets mixed 
with Easythick at thickness level 900. The data shows 
mean ± standard error for 3 replicates. 
 
 
At level 900, which is the thickest consistency in 
Australia prescribed for individuals with 
dyphagia, Easythick significantly delayed 
dissolution of all four medicines tested. Because 
of this, we further investigated the product range, 
choosing a similar product that is also based 
primarily on xanthan gum (Janbak F) and 
products that are comprised of other gum and 
starch thickeners. All five tested retarded release 
of atenolol, which was unaffected by any of the 
food and drink products tested, when used at level 
900.  Furthermore, the thickeners based on 
xanthan gum also affected dissolution when used 
at the intermediate thickness, level 400. Other 
countries may use even thicker consistencies, for 
example in the USA the thickest level is ‘spoon 
thick’ which is 50 >1750 cP (18), which may be 
expected to retard drug release to an even greater 
extent than that observed here. 
Thick food products such as honey, jam and 
yoghurt, which are also used to aid delivery of 
crushed medications for people who cannot or do 
not like to swallow whole tablets and capsules, 
had a relatively small and drug-dependent impact 
on dissolution. In particular, we found that jam 
delayed the dissolution of amlodipine in 
comparison to whole and crushed tablets, and 
yoghurt was associated with large variation in 
dissolution between replicate tests for amlodipine 
and carbamazepine. While jam, yoghurt and 
honey slowed dissolution for crushed 
carbamazepine and warfarin, this actually served 
to create a release profile that was more like that  
 
 
 
of the whole tablet than the crushed tablet, which 
reinforces the fact that each dosage form has the 
potential to respond differently to crushing and 
mixing with vehicles such as these. 
The Biopharmaceutical Classification Scheme 
(BCS) classifies drugs according to two major 
physicochemical properties, solubility and 
permeability, that contribute to bioavailability 
upon oral administration (32).  
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Figure 3.  Dissolution profiles in simulated gastric 
fluid for crushed atenolol tablets mixed with the 
thickened fluids Easythick Advanced, Janbak F, 
Karicare, Nutilis and Viscaid at three viscosity levels: 
a) level 150, b) level 400 and c) level 900. The data 
shows mean ± standard error for 3 replicates. 
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Table 4.  The percentage dissolution (mean ± standard error; n = 3) in simulated gastric fluid at 30 minutes for 
atenolol mixed in water or a thickened fluid prepared at three thickness levels. Measurements with the same 
superscript letter are not significantly different (P<0.05). 
 Percentage of drug dissolved at 30 minutes
Whole tablets with water 97.0 ± 2.7 a 
Crushed tablets in water 96.0 ± 0.9 a 
Crushed tablets in thickener at: Level 150 Level 400 Level 900 
 Easythick Advanced 87.0 ± 2.3 acf 68.0 ± 5.8 bcg 36.2 ± 1.4 d 
 Janbak F 75.6 ± 8.2 ace 46.0 ± 5.1 bd 42.2 ± 6.0 dg 
 Karicare 96.5 ± 5.0 a 97.6 ± 6.4 a 53.3 ± 11.1 deg 
 Nutilis 85.9 ± 0.4 acf 86.6 ± 2.9 acf 47.1 ± 3.4 dg 
 Viscaid 88.1 ± 0.8 acf 91.0 ± 1.3 ac 61.5 ± 8.7 defg 
 
 
 
Table 5. Viscosity (measured at a shear rate of 50 s-1) of the dissolution media at 15 minutes and 3 hours of the 
dissolution test following addition of 15 g of thickened fluid at prepared at level 900 thickness. Also shown is the 
concentration and viscosity of the dissolution media if dispersion of the vehicle was complete, achieved by thoroughly 
mixing the quantity of thickener powder that would be used to prepare 15 g thickened fluid at level 900 into 900 ml 
SGF. For comparison, the viscosity of water and SGF at 50 s-1 is 0.8 cP. 
 Dissolution media viscosity (cP)a Complete dispersion 
Vehicle 15 minutes 3 hours  concentration (%w/v)   viscosity (cP)b 
Easythick 
Advanced 
0.81 1.10 0.07 5.24 
Janbak F 0.80 1.56 0.04 5.92 
Karicare 0.80 1.30 0.67 1.66 
Nutilis 0.81 0.93 0.27 2.19 
Viscaid 0.82 0.82 0.02 1.09 
aAR-G2 cone and plate fixture,  bAR 1500ex concentric cylinder 
 
 
Active ingredients with high solubility and high 
permeability profile are BCS class I substances, 
and amlodipine is an example (37). For these 
drugs it is the dosage form that is likely to be the 
rate limiting step for absorption and so we may 
expect the delay in dissolution exhibited 
particularly by the thickened fluid could translate 
into a clinically significant effect. BCS class II 
compounds exhibit low solubility with high 
permeability, so the dosage form can potentially 
further hinder dissolution and therefore 
absorption. Carbamazepine is within this class 
(38, 39), as exhibited by the slow dissolution of 
the whole tablet which was improved by crushing. 
Warfarin has been classified as BCS class I when 
used as the sodium salt and tested in water (37, 
38) and BCS II when used as the free acid (39) 
slow dissolution from the whole warfarin sodium 
tablet tested in simulated gastric fluid (causing the 
warfarin to become unionized and therefore less 
soluble) suggests that BCS II classification is 
most appropriate for the conditions in our study. 
Both carbamazepine and warfarin have a narrow 
therapeutic index and are associated with serious 
side effects if bioavailability is inconsistent, so 
the significant delay in dissolution caused by 
thickened fluids is a concern. Drugs with high 
solubility but low permeability are grouped into 
BCS class III, and in this study atenolol is the 
example (39). While alterations to dissolution rate 
caused by the dosage form may be of relatively 
low importance for BCS III medications, for 
which absorption is mostly limited by 
permeability, the extent of the delay in drug 
release caused by thickened fluids at level 900 
may have the potential to have a clinically 
significant effect. 
There is the potential for interactions between 
food components, drugs, dosage form excipients 
and gastrointestinal contents (40). Food vehicles 
can form a physical barrier that prevents mixing 
with gastrointestinal fluids, making drug release 
difficult and reducing exposure of the active 
ingredient at the site of absorption (41-43). For 
example, jam contains pectin, which forms a gel 
network that is strengthened by the presence of 
fruit pieces (44), and this is likely to be 
responsible for retarding amlodipine dissolution 
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in this study. However, it is clear that at certain 
concentrations the thickening agents, particularly 
those based primarily on xanthan gum, produced 
much more of a barrier to drug release. Viscosity 
at a single shear rate of 50 s-1 is not a good 
indicator for likelihood of impeding drug 
dissolution. 
The thickening agents are all comprised of 
natural gums and starches which hydrate and form 
highly shear thinning viscoelastic solutions, some 
of which were gel-like, when added to water. 
Polymer solution rheology depends on the 
concentration, conformation in the solvent (e.g. 
water) and interaction between polymer chains 
(45). The conformation of xanthan gum chains is 
rigid rod type (46). In contrast, polymer chains of 
galactomannans (guar gum) are flexible random 
coil type whose shape continually fluctuates (47), 
while starch is highly branched polymer that 
forms swollen granules (48).  Xanthan gum is the 
only polymer that carries a charge; while there 
could be the potential for direct interaction with 
charged drugs, the nutritional information for all 
of the thickeners indicate that they contain sodium 
(e.g. Easythick Advanced 1.5 g/100g, Janbak F 
1g/100g) and this would be expected to form 
ionic interactions with the acidic groups of the 
xanthan gum. Consequently it is most likely that 
the highly ordered xanthan gum network simply 
traps drug molecules within it, and at the higher 
concentrations of xanthan gum (level 400 and 
level 900) this significantly impaired drug 
dissolution and diffusion into the surrounding 
simulated gastric fluid. At the greatest thickness 
(level 900), the networks formed by the other 
products were entangled enough to affect drug 
dissolution. The fact that thickening agents 
containing natural gums are associated with a 
propensity to impair drug dissolution is 
unsurprising, since they are able to impart 
sustained-release properties to solid dose 
formulations. Notably, xanthan gum is better able 
than guar gum to retard drug release (49-51). 
These structured fluids have shear 
thinning and solid-like behaviour. At low shear 
stresses, the solutions exhibit higher viscosity. 
Once the shear stress applied is above a critical 
value, the solutions yield, flow or fracture and 
viscosity drops (45). In the dissolution vessel, 
which represents the physiological conditions 
within the stomach, the shear rates within the 
media are expected to distribute from 0.2 to 92 s-
1at 50 rpm (52). Clearly there are limitations to 
the conclusions that can be drawn when a simple 
dissolution environment is used. Further research 
is required to consider other issues, particularly 
the effect of swallowing on bolus structure and 
integrity as this would be expected to alter drug 
release profile. It is possible that forces acting 
during swallowing may break up the single lump 
of gel into multiple smaller lumps before it gets to 
the stomach. Alternatively, with impaired 
swallowing some of the thickened fluid may 
remain in the pharynx and be delayed in reaching 
the stomach. Shear rates within the oral cavity, 
pharynx and oesophagus vary as a function of 
both physiological and bolus variables. Tongue 
pressure and coordination, in addition to saliva 
lubrication characteristics will affect speed of 
movement and potential deformation of the bolus. 
The viscosity, density, yield stress and elastic 
properties of the bolus interact with these 
physiological variables. Combined, these factors 
will have most impact for individuals with 
dysphagia where tongue strength and control is 
often impaired and there can be severe deficits in 
over- or under-production of saliva (53, 54). 
Although the shear rate of 50 s-1 is most often 
reported to express the shear rate associated with 
swallowing, there is little evidence to support this 
and it is likely that there are a broad range of 
shear rates operating within the deglutitive system 
(45, 55-57).   
 
CONCLUSION 
 
Coadministration of immediate release crushed 
tablets with food based vehicles or thickening 
agents provides a functional approach to medicine 
administration as it reduces the discomfort caused 
by solid dosage forms for patients with 
swallowing difficulties, but with it comes the 
potential for unexpected drug release and 
dissolution profiles. In vitro release and 
dissolution of medications when crushed and 
mixed with common food vehicles or thickening 
agents may be influenced by the properties (e.g. 
viscosity) and structure of the carrier. This may be 
critical for certain medications with a narrow 
therapeutic index or when immediate release is 
required for fast therapeutic action. These 
findings bring into question the potential clinical 
implications of the addition of these agents to 
medications for the purpose of dose delivery and 
indicate that further investigation of thickened 
fluids and their potential to influence therapeutic 
outcomes is warranted. 
 Where the addition of a vehicle is 
considered clinically necessary to aid medication 
delivery, yoghurt is the most appropriate of the 
products tested in this study because it can 
produce the mechanical profile required for oral 
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processing in dysphagic patients without severely 
limiting drug dissolution. However, variability in 
composition and textural attributes between 
brands needs to be considered. Honey and jam 
also have an appropriately high viscosity for oral 
processing without a major delay in dissolution, 
but they have an adhesive quality that makes them 
sticky in the mouth, there are large variations 
between brands and product type, and their high 
sugar content makes them generally unsuitable for 
regular use due to issues with dental care. Where 
possible, dose alteration (e.g. crushing medicines) 
should be avoided and alternate dose forms or 
routes of administration should be found. 
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